Abstract Search

ea0084ps3-15-134 | Thyroid Cancer Diagnosis & Treatment | ETA2022

Patient-reported outcomes (PROS) from patients with RET-mutant medullary thyroid cancer (MTC) and ret fusion-positive TC treated with pralsetinib in the arrow trial

Hadoux Julien , I Hu Mimi , S. Brose Marcia , Garralda Elena , Spitzweg Christine , Reguart Noemi , Do Cao Christine , D. Forster Martin , Alonso-Gordoa Teresa , Barata Teresa , Scalori Astrid , Zalutskaya Alena , Trask Peter , Subbiah Vivek

Objectives: RET alterations are targetable oncogenic drivers in TC. Patients with TC, especially those with MTC treated with the multikinase inhibitors cabozantinib and/or vandetanib (C/V), often experience significant treatment-related side effects. Pralsetinib, a selective RET tyrosine kinase inhibitor, showed efficacy in patients with RET-altered TC from the phase 1/2 ARROW trial (NCT03037385). We present the impact of pralsetinib on PROs in patients with ...

4 shares

Endocrine Abstracts

Patient-reported outcomes (PROS) from patients with RET-mutant medullary thyroid cancer (MTC) and ret fusion-positive TC treated with pralsetinib in the arrow trial

BiosciAbstracts